Merck & Company (NYSE: MRK) — Company Overview, News & Financial Data
Merck is a global pharmaceuticals company focused on innovative health solutions like medicines and vaccines.
Merck & Company
Merck & Company is a global healthcare enterprise that discovers, develops, manufactures, and markets biopharmaceutical prescription medicines, vaccines, biological therapies, and animal health products. The company operates through two main business segments: Pharmaceutical and Animal Health. Its pharmaceutical portfolio includes treatments across oncology, infectious diseases, cardiometabolic disorders, immunology, neuroscience, and respiratory conditions. Additionally, the organization develops and supplies vaccines for pediatric, adolescent, and adult populations, alongside veterinary medicines and health management products for livestock and companion animals worldwide.
Snapshot
Operations
Products and/or services of Merck & Company
- Oncology Therapeutics: Monoclonal antibodies and immunotherapies designed for cancer treatments, targeting programmatic cell death proteins across multiple solid tumor types, hematologic malignancies, and early-stage disease settings across international markets.
- Vaccines Portfolio: Human vaccines covering pediatric, adolescent, and adult immunizations for human papillomavirus, pneumococcal disease, rotavirus, measles, mumps, rubella, and varicella distributed to global health programs and clinical networks.
- Cardiometabolic and Respiratory Medicines: Pharmaceutical treatments targeting pulmonary arterial hypertension, type 2 diabetes, hypercholesterolemia, and chronic heart failure administered through oral formulations and specialized therapies across healthcare systems worldwide.
- Infectious Disease Treatments: Antiviral and antibacterial formulations providing therapeutic interventions for human immunodeficiency virus infections, severe fungal infections, cytomegalovirus in transplant recipients, and hospital-acquired bacterial infections.
- Immunology and Neuroscience Products: Targeted pharmaceutical biologicals and small molecule drugs engineered to manage autoimmune conditions, chronic inflammatory disorders, neurodegenerative conditions, and central nervous system disorders worldwide.
- Animal Health Solutions: Veterinary pharmaceuticals, biological products, vaccines, and digital livestock intelligence services for livestock, poultry, aquaculture, and companion animals distributed to veterinarians, producers, and pet owners globally.
Merck & Company executive team
- Robert M. DavisChairman, President & CEO
- Caroline A. LitchfieldExecutive VP & CFO
- Jennifer L. ZacharyExecutive VP & General Counsel
- Dean Y. LiExecutive VP & President of Merck Research Laboratories
- Dalton E. Smart IIISenior VP of Finance, Principal Accounting Officer & Global Controller
- Gaurav K. GuptaExecutive Vice President and Chief Information & Digital Officer
- Peter DannenbaumVice President of Investor Relations
- Chirfi GuindoExecutive Vice President of Strategic Access, Policy & Communications
- Betty D. LarsonExecutive VP & Chief Human Resources Officer
- Richard R. DeLuca Jr.Executive VP & President of Merck Animal Health
Latest news about Merck & Company
Merck raises FY profit outlook as Q3 revenue climbs 5% to $18.1B
United StatesEU approves Merck’s KEYTRUDA-Padcev bladder cancer regimen
United StatesMerck agrees to $1.3 billion Silence acquisition
United StatesMerck reports Phase 2b tulisokibart HS trial results
United StatesMerck licenses $2.13 billion KRAS cancer drug
United StatesMerck gains FDA approval for kidney cancer treatment
United States
Dividend history
Dividends per share paid by Merck & Company, by financial year.
| Financial year | Interim | Final | Special | Total |
|---|---|---|---|---|
| FY2026(to date) | — | — | — | $2.5500 |
| FY2025 | — | — | — | $3.2800 |
| FY2024 | — | — | — | $3.1200 |
| FY2023 | — | — | — | $2.9600 |
| FY2022 | — | — | — | $2.8000 |
Key financials
Reported results for Merck & Company, in USD.
- Market cap
- 349.9B
- Revenue (TTM)
- 66.6B
- P/E ratio
- 112.6
- EPS (diluted, TTM)
- 1.3
- Dividend yield
- 2.4%
- Profit margin
- 4.8%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 64.9B | 23.5B | 18.3B | |
| 64.2B | 20.2B | 17.1B | |
| 60.1B | 3B | 365M | |
| 59.3B | 18.3B | 14.5B |